Oncopeptides’ Pepaxto divides investigators on superiority potential in Phase III myeloma trial; FDA …,

ClinicalTrials.gov states HORIZON included patients in the 3L and beyond, although the trial’s recruited patients have a median of five prior lines of …, ClinicalTrials.gov states HORIZON included patients in the 3L and beyond, although the trial’s recruited patients have a median of five prior lines of …, Read More

Scroll to Top